Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Progression 63% Improvement Relative Risk Progression (b) 52% Progression (c) 43% c19early.com/ex Malisoux et al. NCT04380987 Exercise Prophylaxis Favors exercise Favors inactivity
Malisoux, 224 patient exercise study: 63% lower progression [p=0.05] https://c19p.org/malisoux
copied to clipboard
Associations between physical activity prior to infection and COVID-19 disease severity and symptoms: results from the prospective Predi-COVID cohort study
29 Apr 2022    Source   PDF   Share   Tweet
Retrospective 452 participants in Luxembourg, showing lower risk of moderate cases with higher physical activity.
risk of progression, 63.0% lower, OR 0.37, p = 0.045, high activity levels 115, low activity levels 108, moderate case, >82 vs. <30 MET-hour/week, RR approximated with OR.
risk of progression, 52.0% lower, OR 0.48, p = 0.14, high activity levels 116, low activity levels 108, moderate case, >52-82 vs. <30 MET-hour/week, RR approximated with OR.
risk of progression, 43.0% lower, OR 0.57, p = 0.28, high activity levels 113, low activity levels 108, moderate case, 30-52 vs. <30 MET-hour/week, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Malisoux et al., 29 Apr 2022, retrospective, Luxembourg, peer-reviewed, survey, median age 42.0, 6 authors, study period May 2020 - June 2021, trial NCT04380987 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperExerciseAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit